Speed spying: adaptive clinical trials hit the gas

* NEWS * 04 August 2019 The I-SPY 2 breast cancer clinical trial paves the way for multi-arm adaptive learning trials. By * Mark Zipkin0 * Mark Zipkin * Haddon Township, NJ, USA. The

multi-armed I-SPY 2 breast cancer clinical trials are starting to fulfill the promises of smarter, more efficient, biomarker-driven trials long touted by reformers (_Nat. Biotechnol._ 25,

287–292, 2007). I-SPY 2 has now sped six drug candidates or combinations to phase 3 and has inspired a generation of Bayesian adaptive platform trials beyond breast cancer applications.

ACCESS OPTIONS Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $29.99 / 30 days cancel any time Subscribe to this journal Receive

12 print issues and online access $209.00 per year only $17.42 per issue Rent or buy this article Prices vary by article type from$1.95 to$39.95 Prices may be subject to local taxes which

are calculated during checkout ADDITIONAL ACCESS OPTIONS: _Nature Biotechnology_ 37, 975-977 (2019) _doi: https://doi.org/10.1038/d41587-019-00021-8_